A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.
Hu L, Li B, Chen G, Song D, Xu Z, Gao L, Xi M, Zhou J, Li L, Zhang H, Feng Q, Wang Y, Lu K, Lu Y, Bu W, Wang H, Wu X, Zhu W, Shi J.
Hu L, et al. Among authors: li l, li b.
J Exp Clin Cancer Res. 2020 Jun 9;39(1):105. doi: 10.1186/s13046-020-01597-9.
J Exp Clin Cancer Res. 2020.
PMID: 32517809
Free PMC article.